Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24.
The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large-cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends.
The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
Comments
Log in or sign up to join the conversation.